SCHEMBL5897206

SCHEMBL5897206

O=C(Nc1ccc(Cl)c(NC(=O)c2ccc(Cl)nc2)c1)c1ccnc(N2CCOCC2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.62
MAPK14 Q16539 6/20 0.61
SMN1; SMN2 Q16637 4/20 0.56
KDM4E B2RXH2 1/20 0.56
MAPK13 O15264 2/20 0.55
TDP1 Q9NUW8 1/20 0.54
RAF1 P04049 3/20 0.54
BRAF P15056 3/20 0.54
ALDH1A1 P00352 2/20 0.53
GAA P10253 1/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
LMNA P02545 2/20 0.51
HTT P42858 2/20 0.51
PPARG P37231 1/20 0.51
MAPK1 P28482 1/20 0.50
HSPB1 P04792 1/20 0.49
MAPK12 P53778 1/20 0.49
MAPK11 Q15759 1/20 0.49
POLB P06746 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5896834 0.92 MAPK14 (0.66) MAPTMAPK14SMN1; SMN2MAPK13RAF1
SCHEMBL5897092 0.91 MAPK14 (0.71) MAPTMAPK14MAPK13TDP1RAF1
SCHEMBL5897367 0.91 MAPK14 (0.67) MAPTMAPK14SMN1; SMN2MAPK13RAF1
SCHEMBL5897072 0.87 MAPK14 (0.64) MAPK14MAPK13RAF1BRAFPPARG
SCHEMBL5896925 0.84 MAPK14 (0.57) MAPK14MAPK13RAF1BRAFPPARG
SCHEMBL5896972 0.83 MAPK14 (0.56) MAPK14SMN1; SMN2MAPK13RAF1BRAF
SCHEMBL5896587 0.82 MAPK14 (0.53) MAPTMAPK14SMN1; SMN2MAPK13RAF1
SCHEMBL402859 0.82 MAPT (0.64) MAPTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL5897374 0.82 MAPK14 (0.58) MAPK14MAPK13RAF1BRAFHSPB1
SCHEMBL5897239 0.82 MAPT (0.66) MAPTMAPK14SMN1; SMN2KDM4EMAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7060700-B2 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB (SE) 2006-06-13 US disclosed
US-20030105142-A1 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB 2003-06-05 US disclosed
US-6432949-B1 Amide derivatives useful as inhibitors of the production of cytokines ASTRAZENECA AB (SE) 2002-08-13 US disclosed
EP-1102750-A1 AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES AstraZeneca AB (SE) 2001-05-30 EP disclosed
WO-2000007991-A1 AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES ASTRAZENECA AB (SE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105142-A1 Amide derivatives useful as inhibitors of the production of cytokines IL6, IL6ST, IL2 MAPT 4663/4885MAPK14 2563/4885SMN1; SMN2 3728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.